Liwanli Innovation CoTPE:3054 -1.09%61 PE Ratio without NRI is 32.90 as of Jul. 06, 2026, which is 35% below its 10-year median of 50.32. GuruFocus rates TPE:3054 with a GF Score™ of 61/100 and a GF Value™ of NT$39.87 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 654 Drug Manufacturers companies, Liwanli Innovation Co ranks worse than 67.74% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-06), Liwanli Innovation Co's share price is NT$63.60.
Liwanli Innovation Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.93. Therefore, Liwanli Innovation Co's PE Ratio without NRI for today is 32.90.
During the past 13 years, Liwanli Innovation Co's highest PE Ratio without NRI was 738.89. The lowest was 15.49. And the median was 50.32.
Liwanli Innovation Co's EPS (Basic) for the
three
months ended in Dec. 2025 was NT$1.30.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.96.
Liwanli Innovation Co (TPE:3054) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Liwanli Innovation Co PE Ratio without NRI Related Terms
Liwanli Innovation Co PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Liwanli Innovation Co's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:3054 vs ZTS, UTHR: PE Ratio without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's PE Ratio without NRI falls into.
Liwanli Innovation Co PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Liwanli Innovation Co's Share Price of today is NT$63.60.
Liwanli Innovation Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.93.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Liwanli Innovation Co (TPE:3054) has a PE Ratio without NRI of 32.90 as of Jul. 06, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Liwanli Innovation Co and its competitors. This is 35% below median its historical median of 50.32. Over the past decade, Liwanli Innovation Co's PE Ratio without NRI has ranged from 15.49 to 738.89. According to the industry distribution chart, Liwanli Innovation Co ranks #443 out of 654 companies in the Drug Manufacturers industry, placing it in the top 67.7%.
Is Liwanli Innovation Co's PE Ratio without NRI too high?
Liwanli Innovation Co's current PE Ratio without NRI of 32.90 is 35% below median its 10-year median of 50.32. Over the past 10 years, this metric has ranged from a low of 15.49 to a high of 738.89. The Drug Manufacturers industry median PE Ratio without NRI is 21.09. Liwanli Innovation Co's value of 32.90 is 56% above this industry median. Based on the distribution chart, Liwanli Innovation Co ranks #443 out of 654 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Liwanli Innovation Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's PE Ratio without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #443 out of 654 companies for PE Ratio without NRI. This places Liwanli Innovation Co in the lower half of its industry. The industry median PE Ratio without NRI is 21.09. Liwanli Innovation Co's value of 32.90 is 56% above this benchmark. Historically, Liwanli Innovation Co's own PE Ratio without NRI has ranged from 15.49 to 738.89 over the past decade. While the company's 10-year median is 50.32 vs. the industry median of 21.09, Liwanli Innovation Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 21.09, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current PE Ratio without NRI of 32.90 is 56% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 21.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current PE Ratio without NRI is 32.90, which is 35% below median its own 10-year median of 50.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.87, compared to a current price of NT$63.60 — trading 59.5% above its estimated fair value. The current PE Ratio without NRI is 32.90, which is 35% below median its 10-year median of 50.32 and 56% above the Drug Manufacturers industry median of 21.09. Liwanli Innovation Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current PE Ratio without NRI is 32.90 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be overvalued.
The current stock price of NT$63.60 is trading 59.5% above its estimated GF Value™ of NT$39.87.
GuruFocus considers Liwanli Innovation Co to be Significantly Overvalued.
Key valuation signals for TPE:3054:
PE Ratio without NRI: 32.90 (35% below median its 10-year median of 50.32)
GF Value™: NT$39.87 vs. price of NT$63.60 (59.5% above fair value)
Industry Position: 56% above the Drug Manufacturers median (#443 of 654)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
61GF Score
Get the complete analysis for TPE:3054
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
